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Over the past decade major advances have been made in our
understanding of the molecular machinery that mammalian
cells use to sense and to adapt to a low-oxygen environment.
A critical mediator of cellular adaptation to hypoxia is
hypoxia-inducible factor (HIF), a basic helix-loop-helix
transcription factor that consists of an oxygen-sensitive
a-subunit, HIF-a and a constitutively expressed b-subunit,
HIF-b. Under conditions of normal oxygen tension, the
HIF-a subunit is hydroxylated by specific prolyl-hydroxylases
and targeted for rapid proteasomal degradation by the von
Hippel–Lindau (VHL) tumor suppressor, which is the substrate
recognition component of an E3-ubiquitin ligase. In a
hypoxic environment or in the absence of functional
VHL tumor suppressor protein irrespective of oxygen
concentration, HIF-a is not degraded and translocates to
the nucleus, where it dimerizes with HIF-b to form
transcriptionally active HIF. As a transcription factor, HIF is
involved in the regulation of many biological processes that
facilitate both oxygen delivery and adaptation to oxygen
deprivation by regulating genes that are involved in glucose
uptake and energy metabolism, angiogenesis, erythropoiesis,
cell proliferation and apoptosis, cell–cell and cell–matrix
interactions, and barrier function. This review summarizes
some of the most recent advances in the VHL/HIF field and
discusses their relevance for pathogenesis and treatment of
acute ischemic renal failure, renal fibrosis, and renal cancer.
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OVERVIEW OF REGULATION OF HIF SIGNALING
Key mediators of cellular adaptation to hypoxia are hypoxia-
inducible factors (HIFs), HIF-1 and HIF-2 being the most
prominent and best characterized (for recent reviews, see
Wenger1 and Pugh and Ratcliffe2). HIF-1 and HIF-2 (for the
purpose of this review collectively referred to as HIF) are
members of the PAS (per/aryl-hydrocarbon-receptor nuclear
translocator (ARNT)/Sim) family of basic helix-loop-helix
transcription factors. They consist of an oxygen-sensitive
a-subunit and a constitutively expressed b-unit, also known
as the ARNTor simply HIF-b.1,2 As global regulators of oxygen
homeostasis, these heterodimeric transcription factors
facilitate both oxygen delivery and adaptation to oxygen
deprivation by regulating the expression of gene products
that are involved in cellular energy metabolism (e.g.
phophoglycerate kinase-1 and glucose transporter-1
(GLUT-1)), angiogenesis (e.g. vascular endothelial growth
factor (VEGF)), erythropoiesis (erythropoietin (EPO)),
apoptosis and proliferation (B-cell lymphoma-2 family
members, cell cycle regulators p21 and p27) and other
biological processes.1,2 Direct transcriptional regulation
occurs through the binding of HIF heterodimers to hpoxia-
response-elements present in regulatory elements of many
hypoxia-sensitive genes (Figure 1). The list of HIF target
genes has grown rapidly and includes genes that have
well-demonstrated relevance to the pathogenesis of acute
and chronic kidney diseases. These include among others
hemeoxygenase-1, VEGF, plasminogen activator inhibitor-1,
tissue-inhibitor of metalloproteinase-1, and connective tissue
growth factor.1,3 HIF-1 and HIF-2 do not completely overlap
with regard to their ability to transcriptionally regulate
specific hypoxia responsive genes. For example, glycolytic
genes appear to be predominantly regulated by HIF-1,4
whereas it has been suggested by our group and others that
HIF-2 is the main regulator of VEGF and EPO expression in
tissues that express both HIF-1 and HIF-2.5,6
HIF activation is dependent upon stabilization of the
oxygen-sensitive a-subunit and its subsequent translocation
to the nucleus where it forms a functional complex with
ARNT and transcriptional co-activators such as CBP/p300.1,2
Normally, under conditions of adequate oxygen supply, HIF-a
binds to the von Hippel-Lindau tumor suppressor protein
(pVHL), which is part of an E3-ubiquitin ligase complex that
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targets HIF-a for proteasomal degradation (Figure 1). All
three known HIF-a subunits, HIF-1a, HIF-2a, and HIF-3a
(the role of HIF-3a in hypoxic signaling is unclear, a HIF-3a
splice variant, inhibitory PAS (IPAS), may be inhibitory7)
have been shown to interact with pVHL. This interaction is
highly conserved between species and requires iron- and
oxygen-dependent hydroxylation of defined proline residues
within the oxygen-dependent degradation domain of HIF-a
by HIF-prolyl-hydroxylases. Prolyl-hydroxylation and bind-
ing to pVHL are absolutely required for the execution of HIF
proteolysis under normoxia. During hypoxia, prolyl-hydro-
xylation is inhibited and HIF-a is stabilized and not
degraded. Loss of pVHL function also results in HIF-a
stabilization, increased HIF transcriptional activity, and
upregulation of HIF target genes such as VEGF, glucose
transporter-1, and EPO, but is independent of oxygen levels.
This explains some of the clinical features that are associated
with VHL-deficient tumors, for example, the high degree
of vascularity, which is a consequence of excessive VEGF
production. A second hypoxic switch operates in the
carboxy-terminal transactivation domain of HIF-a with the
hydroxylation of an asparagine residue; in hypoxia, aspar-
agine hydroxylation is blocked and CBP/p300 recruitment
is facilitated enabling increased levels of transcription
(Figure 1). Besides hypoxic activation, a non-hypoxic in-
crease in HIF transcriptional activity has been shown to be
mediated by nitric oxide, tumor necrosis factor-a,8 and
angiotensin II,9 and others.1 Thus, it is easy to imagine that
HIF activation is likely to occur in a variety of different renal
disease settings independent of significant hypoxia.
While HIF-1, initially identified as the factor that regulates
the hypoxic induction of EPO, appears to be ubiquitously
expressed, HIF-2 expression is more restricted.10 Cell types
that express HIF-2a include hepatocytes, cardiomyocytes,
glial cells, type-II pneumocytes, and endothelial cells.10 In the
kidney, HIF-regulated gene expression in normal, non-
transformed primary renal tubular epithelial cells appears
to be solely controlled by HIF-1.3 In the adult rodent, HIF-2a
was found in renal interstitial and renal endothelial cells
under conditions of carbon-monoxide poisoning or renal
ischemia.10,11
VHL AND HIF IN RENAL CANCER DEVELOPMENT
Inactivation of pVHL results in HIF-a stabilization, increased
HIF transcriptional activity, and upregulation of HIF target
genes. Patients with germline mutations in pVHL are pre-
disposed to develop VHL disease, an autosomal dominant
familial tumor syndrome that follows Knudson’s two-hit
hypothesis (loss of the remaining wild-type allele in tumors)
and is characterized by the development of highly vascular-
ized benign and malignant neoplasms at multiple organ sites,
which include renal cysts and renal cell carcinomas.12 Besides
its role in familial renal cancer, VHL gene mutations are
found in the majority of sporadic renal cell carcinoma of the
clear cell type (CC-RCC), which is the most common form of
kidney cancer. VHL associated CC-RCCs are often preceded
by pre-neoplastic renal cysts, which are typically multifocal
and bilateral in patients with VHL disease. Although it is
widely believed that VHL associated renal tumors originate
from the proximal nephron, it was recently reported that in
kidneys from VHL patients, ‘early’ multicellular lesions
appeared to be more frequently derived from Tamm–Horsfall
protein-expressing distal tubular segments than from the
proximal renal tubule. Interestingly, single cell foci of
increased HIF-target gene expression were found more
frequently in proximal tubular cells, suggesting a site-specific
tumor suppressor function for pVHL in the kidney.13 This
finding raises the possibility that VHL-associated renal
lesions arise from the distal nephron and should stimulate
new studies into their exact histogenetic origin.
Although the highly vascular nature of VHL-deficient
tumors is easily explained by increased HIF activity resulting
in increased vascular growth factor production, VHL-
associated carcinogenesis is more difficult to understand
and most likely requires additional genetic events. Besides
regulating the degradation of HIF-a subunits, pVHL has been
shown to play a role in fibronectin extracellular matrix
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Figure 1 | The pVHL–E3-ubiquitin ligase targets hydroxylated
HIF-a for proteasomal degradation. Under normoxia, hydroxylation
of HIF-a subunits by prolyl-hydroxylases is required for binding to
the pVHL–E3-ubiquitin ligase complex. After polyubiquitination,
HIF-a is degraded by the proteasome. During hypoxia or when
prolyl-hydroxylases are inhibited pharmacologically, or in the
absence of functional pVHL irrespective of oxygen tension, HIFa
subunits are not degraded and translocate to the nucleus where they
bind to the HIF-b subunit ARNT. HIF-a/ARNT heterodimers then
bind to HIF-DNA consensus-binding sites resulting in increased
transcription of HIF-target genes, for example, EPO, VEGF, and glucose
transporter-1. Factor-inhibiting-HIF (FIH) is an asparagine hydroxylase
that modulates cofactor recruitment to the HIF transcriptional
complex via asparagine hydroxylation of the HIF-a carboxy-terminal
transactivation domain. Also shown is the core sequence (RCGTG) of
a hypoxia-responsive element (HRE). Pro, proline; Asn, asparagine.
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assembly and matrix turnover,14–16 microtubule stability,17
and regulates the stability and/or activity of other proteins
such as plant homeodomain protein Jade-1,18 and atypical
protein kinase C isoforms.19–21 Other pVHL targets have been
described, most notably transcription factor Sp1,22 a kruppel-
associated box (KRAB)-A domain protein, VHLak, repressing
HIF transcriptional activity,23 de-ubiquitinating enzymes,24
the large subunit of RNA polymerase II,25 and the RNA-
binding protein hnRNP A2.26 It is unclear however how other
pVHL functions contribute to renal carcinogenesis. With
regard to the contribution of HIF-1 and/or HIF-2 to VHL
renal tumorigenesis, it is of interest that a substantial number
of VHL-defective CC-RCC cell lines do not express HIF-1a,
but do express HIF-2a.27 This is in contrast to normal, non-
transformed renal epithelial cells in which HIF-2a is not
detectable during ischemia.11 A bias towards HIF-2a expres-
sion was also found in clinical CC-RCC samples (94 versus
69% expressed HIF-2a in CC-RCC with confirmed VHL
defect).28 Thus, VHL-associated tumor development may
depend on a shift in the ratio of HIF-1 versus HIF-2 levels
towards an increase in HIF-2. In support of this hypothesis,
VHL reconstituted 786-O CC-RCC cells transfected with
a non-degradable form of HIF-2a were still able to form
tumors in nude mice thereby overriding pVHL’s tumor
suppressor function,29 whereas the expression of non-
degradable HIF-1a in a similar experimental setting did
not have a tumor promoting effect.30 Consistent with
these findings, inactivation of HIF-2a by RNA interference
suppressed tumor formation in a VHL-deficient back-
ground.31,32 Taken together, these reports suggest that HIF-1
and HIF-2 have diverse functions with regard to VHL renal
tumorigenesis. Whether differential effects on signaling
pathways critical for renal epithelial cell growth may explain
the functional differences between HIF-1 and HIF-2 will have
to be explored in greater detail. Important hypoxia and HIF-
regulated gene products believed to play a key role in the
pathogenesis and progression of CC-RCC include among
others transforming growth factor-a (TGF-a), a potent renal
epithelial mitogen, cell cycle regulator cyclin D1, and
chemokine receptor CXCR4. Activation of the TGF-a/
epidermal growth factor receptor pathway has been suggested
to be the result of a predominantly HIF-2-dependent increase
in TGF-a expression.33,34 Cyclin D1 was found to be
upregulated in VHL-deficient renal cancer cell lines and
in clinical CC-RCC specimen and has been shown to be
hypoxia-regulated in a cell type-specific manner.35–37 Cyclin
D1 promotes cell cycle progression through its interaction
with cyclin-dependent kinase (CDK)4/CDK6 and phosphor-
ylation of the retinoblastoma protein thus allowing S-phase
entry, and therefore is a critical target of pVHL’s tumor
suppressor function. Although the effects of high levels
of HIF target CXCR4 on renal tumor growth itself are not
clear, CXCR4 expression levels correlate with poor survival
and increased metastatic potential, suggesting that this
receptor plays an important role in the clinical progression
of CC-RCC.38
HIF SIGNALING IN RENAL ISCHEMIA REPERFUSION INJURY
During renal ischemia when HIF-a proteolysis is inhibited,
HIF-1a is detected in the nucleus of renal tubular epithelial
cells, where it dimerizes with HIF-1b to form transcription-
ally active HIF-1. By contrast, HIF-2a is undetectable in
this cell type, supporting the notion that HIF-1 is the key
mediator of hypoxic HIF signaling in non-transformed renal
epithelia.10,39 As a global regulator of cellular adaptation
to hypoxia, HIF-1 regulates critical biological processes
important for survival of hypoxic cells such as anaerobic
glycolysis (Pasteur effect), oxygen delivery through increased
angiogenic growth factor production and erythropoiesis, as
well as cellular proliferation and apoptosis. Nevertheless, the
role of HIF-1 in the regulation of mitochondrial signaling,
hypoxic cell death and recovery from ischemia–reperfusion
injury is controversial and most likely context or cell-type
dependent. For example, genetic studies with conditional
knockout mice showed that rodent brains, which were HIF-1
deficient in neurons, were protected from cerebral ischemic
injury.40 By contrast, conventional knockout mice that have
lost one copy of HIF-1a (heterozygously deficient in all cell
types) did worse in a model of myocardial ischemia following
ischemic preconditioning,41 supporting the notion that a cell
survival promoting effect of HIF-1 may be context-depen-
dent. Current studies with kidney-specific HIF-1a knockout
mice have not been published but are in progress.
Despite its controversial role in the execution of acute
hypoxic cell death, HIF-1 is known to upregulate factors that
have been shown to be ‘cytoprotective’ during acute renal
injury including ischemia. These, for example, include
VEGF,42,43 hemeoxygenase-1,44–47 and EPO.48 Pretreatment
of rats with a HIF-specific prolyl-hydroxylase inhibitor to
increase HIF activity,49 or cobalt chloride,50 a chelating agent
known to inhibit HIF-a proteolysis, resulted in improved
renal clearance after clamping of the renal pedicle. Histo-
logically, pretreatment with cobalt chloride was also associated
with amelioration of tubulointerstitial injury with decreased
macrophage infiltration, providing evidence that HIF-1
signaling is involved in ischemic pre-conditioning of the
kidney, as has been proposed for other organ systems.41,51
Although these reports suggest that HIF signaling may
ameliorate acute hypoxic tissue injury, it is unclear which
signaling pathways and which renal cell types mediate this
effect. Nevertheless, these data suggest that pharmacological
inhibition of HIF-a proteolysis with small molecule com-
pounds that inhibit HIF prolyl-hydroxylase activity may be
a useful preventative strategy to improve clinical outcome of
ischemia reperfusion injuries, for example, renal ischemic
injuries that are associated with procedures involving radio-
contrast media, cardiothoracic surgery, or renal cadaveric
transplantation. Preliminary findings furthermore suggest
that certain prolyl-hydroxylase inhibitors may also have
a selective effect on HIF target gene expression and HIF-
controlled biological processes, as they have the potential
to increase iron metabolism and erythropoiesis without
affecting angiogenesis for example.52 Although the molecular
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mechanisms underlying prolyl-hydroxylase inhibitor selec-
tivity are difficult to explain, the development of application-
specific prolyl-hydroxylase inhibitors that target either
erythropoiesis or angiogenesis, or HIF survival pathways
alone would be of tremendous clinical importance.
A POTENTIAL ROLE FOR HIF IN THE PROGRESSION OF
CHRONIC RENAL DISEASE AND TUBULOINTERSTITIAL
FIBROSIS
Hypoxia has long been thought to be a major factor in the
progression of chronic renal diseases irrespective of the
underlying cause.53 This is no surprise, as renal ‘scarring’ is
associated with loss of microvasculature, leading to decreased
blood flow and impaired oxygenation in areas of fibrosis.
However, more recent work has suggested that discrepancies
between oxygen demand and supply can even occur ‘early’
in diseased kidneys before visible scarring is detected.54 The
notion that hypoxia has an important role in the progression
of renal fibrosis raises questions about HIF’s contribution to
this disease process. Potential mechanisms through which
HIF signaling may contribute to renal fibrogenesis include
(a) direct regulation of fibrogenic factors and synergy with
TGF-b1, a potent profibrotic factor, (b) its possible role in
epithelial to mesenchymal transition (EMT), and (c) HIF’s
role in inflammation (Figure 2).
In human renal tubular cells, hypoxia induces collagen I,
decreases matrix-metallopeptidase-2, and increases tissue-
inhibitor of metalloproteinase-1 .55 Hypoxia can also act
synergistically with TGF-b1 in the regulation of certain
hypoxia responsive genes such as VEGF,56 endoglin,57 and
EPO.58 Synergistic effects between hypoxia and TGF-b1 have
furthermore been demonstrated with regard to the produc-
tion of collagens.59,60 These observations and the finding that
several genes, which play critical roles in renal fibrogenesis are
direct HIF-1 targets (e.g. tissue-inhibitor of metalloproteinase-1,61
plasminogen activator inhibitor-1,62 connective tissue growth
factor3), suggest that increased HIF activity is likely to play an
important role in the pathogenesis of tubulointerstitial fibrosis
through direct transcriptional regulation of specific profibrotic
genes and/or through enhancement of TGF-b1 signaling.
Synergistic interaction between MAD homolog (SMAD)-3, a
downstream effector of TGF-b1, and HIF-1 has been suggested
by Sanchez-Elsner et al.56 as a possible mechanism in the
transcriptional regulation of VEGF. Hypoxia may also increase
SMAD3 mRNA levels or promote the thrombospondin-
dependent release of latent TGF-b, as has been shown for
TGF-b2.63 Whereas direct regulation of profibrotic genes by
HIF-1 can be easily investigated, the exact role of HIF-1 in
TGF-b signaling may be complex and more difficult to
understand.
A possible role for hypoxia and HIF-1 in the dediffer-
entiation and transition of renal EMT has been proposed.64,65
This may or may not involve TGF-b1, which is a potent
inducer of EMT. Transition of epithelial to mesenchymal cells
is recognized as a substantial contributor to the development
of renal fibrosis.66 EMT is characterized by the disassembly of
intercellular contacts, such as E-cadherin adherens junctions,
leading to cell–cell separations associated with an increase in
motility and re-organization of the actin-cytoskeleton, which
eventually results in the generation of fibroblast-like cells that
express mesenchymal markers and display increased motility
and invasiveness.66 In a recent, preliminary study by our
group, hypoxia increased the percentage of transitioned renal
epithelial in a HIF-dependent fashion in vitro and in vivo,65
suggesting that HIF-1 may play a direct role in EMT. The
notion that hypoxia and HIF-1 influence the differentiation
state of cells is supported by observations in other cell
systems.67 Although the molecular mechanisms underlying
this effect need further definition, a very recent study by
Gustaffsson et al.68 suggested that HIF-1a through direct
interaction with the intracellular domain of Notch enhances
Notch signaling and in this way may directly be involved in
the maintenance of an undifferentiated state. Whether this
interaction will be important for EMT and the development
of tubulointerstitial fibrosis remains to be investigated.
A third mechanism by which HIF may impact on the
pathogenesis of tubulointerstitial disease is through its role in
inflammation. It is important to realize and is not a surprise,
Tubulointerstitial
fibrosis
EMT
ECM
accumulation
TGF-1
synergy
Hypoxia/HIF
Acute
ischemic renal
injury
Apoptosis
proliferation
Loss of pVHL
Inflammation
Renal tumorigenesis
HIF-independent
functions of pVHL 
Inability to degrade HIF-
expression of HIF-2
+ other
genetic events
HIF-1/2:
EC
IC
HIF-1
Cell–cell and
cell–matrix
interactions
Cyclin D1 
TGF-
CXCR4
Anaerobic
glycolysis
Cytoprotective
factors
Figure 2 | The role of HIF in acute ischemic renal injury,
tubulointerstitial fibrosis, and VHL-associated renal cancer.
Overview of selected hypoxia/HIF-regulated biological processes that
have been shown or have been proposed to play important roles in
the pathogenesis of acute ischemic renal injury, renal fibrosis, and
renal cancer. Shown in red (renal proximal tubule) and blue
(Tamm–Horsfall protein-expressing nephron segments) are the
proposed sites of origin of VHL-associated renal cancer. While HIF-1a
can be found in all nephron segments, HIF-2a in the non-cancerous,
normal kidney is not expressed in renal epithelial cells, but can be
found in renal interstitial and renal endothelial cells. EMT, epithelial
to mesenchymal transition.
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that micro-environmental changes, such as hypoxia, have a
strong impact on inflammatory cell recruitment69 and
function.70 Elegant studies in tissue-specific HIF knockout
mice have shown that HIF-1 is essential for myeloid-cell-
mediated inflammation mainly through its effects on cellular
ATP generation. Absence of HIF-1 resulted in a profound
impairment of myeloid cell aggregation, motility, and
invasiveness, whereas forced expression of HIF-1 had the
opposite effect.69 Since inflammatory responses represent an
important component in the pathogenesis of tubulointer-
stitial fibrosis, it is easy to imagine that HIF signaling in
inflammatory cells may also have a significant role in the
progression of chronic renal disease.
SUMMARY
In this review, I have summarized some of the most recent
findings in VHL and HIF biology and have attempted to
provide the reader with a perspective on how HIF signaling
may impact on the pathogenesis and/or treatment of renal
cancer, and acute and chronic kidney disease. Because of
space limitations I have omitted a discussion on the potential
role for HIF signaling in inflammatory and non-inflamma-
tory glomerular disease. HIF biology in the kidney is still in
its infancy and in the past has largely been dominated by
investigations that examine the VHL tumor suppressor and
HIF in renal carcinogenesis. Over the next 5 years, we can
expect to come across a large number of very exciting genetic
and pharmacological in vivo and cell culture studies that
examine the role of the VHL/HIF oxygen-sensing pathway in
all aspects of kidney pathophysiology. From a clinical point
of view, small molecule compounds that specifically target
HIF-specific prolyl-hydroxylases have high potential to aid in
the treatment of anemia and improve iron metabolism, and
also may impact on the clinical outcome of ischemic renal
injuries and other renal diseases.
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